|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Bronchitis, chronic, acute exacerbation |
|
Genital ulcer disease |
|
Infection, cervix |
|
Infection, ear, middle |
|
Infection, lower respiratory tract |
|
Infection, skin and skin structure |
|
Infection, upper respiratory tract |
|
Mycobacterium avium complex |
|
Pelvic inflammatory disease |
|
Pharyngitis |
|
Pneumonia, community- acquired |
|
Tonsillitis |
|
Urethritis |
| |
|
|
SIDE EFFECTS:
|
|
Thrombophlebitis |
|
Acute interstitial nephritis |
|
allergic reactions |
|
pseudomembranous colitis |
|
Gastrointestinal disturbances |
|
Dizziness |
|
headache |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Hepatic function impairment |
|
|
ADULT DOSE:
|
|
Bronchitis, bacterial exacerbations or
Pharyngitis, streptococcal or
Pneumonia, due to Streptococcus pneumoniae or Haemophilus influenzae , or
Skin and soft tissue infections, uncomplicated, due to Staphylococcus aureus , Streptococcus agalactiae , or Streptococcus pyogenes or
Tonsillitis, streptococcal-Adults and adolescents 16 years of age and older: Oral, 500 mg as a single dose on the first day, then 250 mg once a day on days two through five .
Adolescents up to 16 years of age: Safety and efficacy have not been established .
Cervicitis, nongonococcal or
Urethritis, nongonococcal-Adults and adolescents 16 years of age and older: Oral, 1000 mg as a single dose .
Adolescents up to 16 years of age: Safety and efficacy have not been established . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Children up to 16 years of age-Safety and efficacy have not been established . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|